Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A061202
  • The purpose of this study is to compare the effects, good and/or bad, of the study drugs pomalidomide, ixazomib, and dexamethasone, or the study drugs pomalidomide and dexamethasone, on you and your multiple myeloma to find out which is better. In this study, you will get either the study drugs pomalidomide, ixazomib, and dexamethasone or the study drugs pomalidomide and dexamethasone.

  • Alliance A061402
  • The purpose of this study is to compare any good and bad effects of using a combination of lenalidomide, ixazomib, dexamethasone, and zoledronic acid along with the radiation therapy to using radiation therapy and zoledronic acid alone for your plasmacytoma of the bone.

  • CTSU E1A11
  • The treatment of multiple myeloma has significantly changed as a result of several drugs being introduced for its treatment such as bortezomib, carfilzomib and lenalidomide. All these drugs used with dexamethasone or in combinations that contain more than one of these drugs allow greater control of the disease process. However, we still do not fully understand the best way to combine these drugs and how long the treatment process needs to be continued in order to provide the maximum benefit to the patients. The treatment combinations that are being compared in this study are both effective, but they have different side effects, which can impact whether patients tolerate the treatment for a prolonged time.  

  • SWOG S1702
  • The purpose of this study is to test for any good and bad effects of the study drug called isatuximab.  Isatuximab may or may not improve your AL amyloidosis but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple myeloma.  For this reason, the researchers think that isatuximab may also help patients whose amyloidosis has recurred or gotten worse.